Speakers & Moderators

Etienne Tichit, 54 years old, pharmacist (Paris-Sud University, 1994), and a graduate of INSEAD (2008), Harvard (2015), and IMD (2023), has served as Corporate Vice President and General Manager of Novo Nordisk France since October 2019.
Since January 2021, he has also been Vice President of Public Affairs and Environmental Performance at Polepharma, the leading pharmaceutical network in Europe, which brings together biopharmaceutical stakeholders based in the Centre-Val de Loire, Normandy, and Île-de-France regions.
In 2022, Etienne was tasked by the National Industry Council and FEFIS (French Federation of Healthcare Industries) with designing and overseeing the decarbonization roadmap for the Healthcare Industries and Technologies sector in France.
Throughout his career, Etienne has been driven by a vision of leading both international and national organizations with the goal of making a positive impact on both human health and the planet.
Etienne Tichit began his career in Marketing at Revlon, followed by a role in business development at a healthcare consultancy, before joining the independent Dutch laboratory Norgine (1998–2000), specializing in gastroenterology. In 2000, he joined the French subsidiary of Novo Nordisk, where he managed a strategic partnership with Roche Pharma and later Merck. He subsequently held roles as Marketing Director and Director of Diabetes Commercial Operations. In 2012, Etienne was called to Novo Nordisk's European Regional Headquarters in Switzerland and later Denmark, where he successively held the positions of Corporate Vice President for Commercial Excellence and Corporate Vice President for Marketing & Market Access. During this time, he successfully led the launch of therapeutic innovations across 35 countries in areas such as diabetes, obesity, hemophilia, and growth disorders.
After this 7-year international experience, Etienne was appointed General Manager of Novo Nordisk France, strengthening the company’s unique position in the French healthcare sector. He contributed to the company’s performance in clinical development, sales, sustainability, manufacturing, and by promoting diversity and inclusion.